{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:05:34Z","timestamp":1784001934808,"version":"3.55.0"},"reference-count":128,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>With a lifetime risk estimated to be 1 in 8 in industrialized countries, breast cancer is the most frequent type of cancer among women worldwide and the second leading cause of cancer deaths in women. More importantly, current evidence suggests that in women aged &lt;45 years, breast cancer is unquestionably the leading cause of cancer-related deaths. Hormonal therapy has an established role in the treatment of breast cancer. Hormonal therapy aims at preventing the stimulation of mitogenic estrogen-dependent pathways. Hormonal therapy can be performed through blocking the production of estrogens or through blocking the action of estrogens upon tumor cells. The action of estrogens upon tumor cells can be blocked through selective estrogen receptor modulators (SERMs) or through selective estrogen receptor downregulators (SERDs). Estrogen receptor mutation (ESR1 mutation) is one of the common mechanisms by which breast cancer becomes resistant to additional therapies from SERMs or aromatase inhibitors. Fulvestrant, an injectable anti-estrogen, is the SERD commonly used. Fulvestrant has no agonistic activity and causes degradation of the estrogen receptor. This agent is more active in postmenopause than premenopause and is indicated in the treatment of advanced breast cancer in case of disease progression during or after tamoxifen. Oral SERDs are being rapidly developed to replace fulvestrant with the potential of higher efficacy and lower toxicities. Novel agents such as complete estrogen receptor antagonists (CERANs), proteolysis targeting chimeras (PROTACs), and selective estrogen receptor covalent antagonists (SERCAs) are also promising therapies. This manuscript focuses on recent advances in the development of drugs targeting the estrogen receptor.<\/jats:p>","DOI":"10.3390\/cimb48070715","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:34:44Z","timestamp":1783996484000},"page":"715","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Estrogen Receptor for Breast Cancer"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9416-6768","authenticated-orcid":false,"given":"Eugenia","family":"Yiannakopoulou","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health and Care Sciences, University of West Attica, 12243 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ijc.27711","article-title":"Global estimates of cancer prevalence for 27 sites in the adult population in 2008","volume":"132","author":"Bray","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrc3518","article-title":"Progesterone signalling in breast cancer: A neglected hormone coming into the limelight","volume":"13","author":"Brisken","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mce.2011.10.030","article-title":"The biology of progesterone receptor in the normal mammary gland and in breast cancer","volume":"357","author":"Obr","year":"2012","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_4","first-page":"831","article-title":"Cumulative number of menstrual cycles and breast cancer risk: Results from the E3N cohort study of French women","volume":"13","year":"2002","journal-title":"Cancer Causes Control"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(2012). Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol., 13, 1141\u20131151.","DOI":"10.1016\/S1470-2045(12)70425-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1158\/0008-5472.CAN-03-0629","article-title":"Hormone-induced chromosomal instability in p53-null mammary epithelium","volume":"64","author":"Pati","year":"2004","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1096\/fj.00-0165com","article-title":"Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells","volume":"14","author":"Goepfert","year":"2000","journal-title":"FASEB J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_9","first-page":"584","article-title":"Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice","volume":"45","author":"Osborne","year":"1985","journal-title":"Cancer Res."},{"key":"ref_10","first-page":"428","article-title":"Hormone receptors: Their role in predicting prognosis and response to endocrine therapy","volume":"5","author":"McGuire","year":"1978","journal-title":"Semin Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Barh, D. (2014). Breast Cancer Therapy\u2013Classical Therapy, Drug Targets, and Targeted Therapy. Omics Approaches in Breast Cancer, Springer.","DOI":"10.1007\/978-81-322-0843-3"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41467-021-25422-9","article-title":"Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer","volume":"12","author":"Alves","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1210\/en.2003-0567","article-title":"Profiling of estrogen up- and down-regulated gene expression in human breast cancers cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype","volume":"144","author":"Frasor","year":"2003","journal-title":"Endocrinology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(00)00024-X","article-title":"The SRC family of nuclear receptor coactivators","volume":"245","author":"Leo","year":"2000","journal-title":"Gene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1043-2760(00)00355-6","article-title":"The TRAP\/SMCC\/Mediator complex and thyroid hormone receptor function","volume":"12","author":"Ito","year":"2001","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0168-9525(00)02060-6","article-title":"The Swi\/Snf family nucleosome-remodeling complexes and transcriptional control","volume":"16","author":"Sudarsanam","year":"2000","journal-title":"Trends Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13505","DOI":"10.1074\/jbc.R000025200","article-title":"CREB-binding protein and p300 in transcriptional regulation","volume":"276","author":"Vo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0092-8674(00)80516-4","article-title":"Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P\/CAF and CBP\/p300","volume":"90","author":"Chen","year":"1997","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"LHRH-agonists in Early Breast Cancer Overview Group, Cuzick, J., Ambroisine, L., Davidson, N., Jakesz, R., Kaufmann, M., Regan, M., and Sainsbury, R. (2007). Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet, 369, 1711\u20131723.","DOI":"10.1016\/S0140-6736(07)60778-8"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer"},{"key":"ref_26","first-page":"1","article-title":"Goserelin (Zoladex)\u2014Its role in early breast cancer in pre- and perimenopausal women","volume":"85","author":"Jonat","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2007.13.5319","article-title":"Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer","volume":"26","author":"Rossi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s40265-017-0849-3","article-title":"Triptorelin: A review of its use as an adjuvant anticancer therapy in early breast cancer","volume":"77","author":"Frampton","year":"2017","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jsbmb.2006.09.003","article-title":"Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant","volume":"102","author":"Ariazi","year":"2006","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"176424","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rej, R.K., Roy, J., and Allu, S.R. (2024). Therapies for the Treatment of Advanced\/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions. Cancers, 16.","DOI":"10.3390\/cancers16030552"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/acs.jmedchem.5b01276","article-title":"Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer","volume":"59","author":"Xiong","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13543776.2022.2006185","article-title":"Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): A patent review (2015-present)","volume":"32","author":"Scott","year":"2022","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103861","DOI":"10.1016\/j.critrevonc.2022.103861","article-title":"New steps on an old path: Novel estrogen receptor inhibitors in breast cancer","volume":"180","author":"Pagliuca","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_39","first-page":"623","article-title":"Addressing unmet need in the management of patients with ER+\/HER2-, ESR1-mutated metastatic breast cancer: Clinician\u2019s perspective","volume":"21","author":"Rugo","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: A clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11864-023-01079-y","article-title":"Novel Estrogen Receptor-Targeted Agents for Breast Cancer","volume":"24","author":"Shastry","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0959-8049(22)00896-6","article-title":"Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and\/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)","volume":"174","author":"Hamilton","year":"2022","journal-title":"Eur. J. Cancer."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"TPS1127","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1127","article-title":"A phase 1b\/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and\/or metastatic estrogen receptor-positive (ER+)\/HER2-negative (HER2-) breast cancer","volume":"41","author":"Borges","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.2021.39.15_suppl.1018","article-title":"Phase I\/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer","volume":"39","author":"Hamilton","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2013.12.011","article-title":"Use of SERMs for treatment in postmenopausal women","volume":"142","author":"Pinkerton","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"The aTTom Collaborative Group (2013). aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J. Clin. Oncol., 31, 18.","DOI":"10.1200\/jco.2013.31.18_suppl.5"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., McGale, P., Pan, H.C., and Taylor, C. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet, 378, 771\u2013784.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","article-title":"Endocrine resistance in breast cancer\u2014An overview and update","volume":"418","author":"Clarke","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0960-9776(11)70293-4","article-title":"Biological mechanisms and clinical implications of endocrine resistance in breast cancer","volume":"20","author":"Giuliano","year":"2011","journal-title":"Breast"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","article-title":"Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy","volume":"100","author":"Li","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: Concept and consequences in cancer","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance","volume":"2","author":"Ali","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"Ring","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00666205","article-title":"Mechanisms of tamoxifen resistance","volume":"32","author":"Osborne","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133853","DOI":"10.1016\/j.molstruc.2022.133853","article-title":"Selective estrogen receptor modulators (SERMs) for the treatment of ER+ breast cancer: An overview","volume":"1270","author":"Das","year":"2022","journal-title":"J. Mol. Struct."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120234","DOI":"10.1016\/j.molliq.2022.120234","article-title":"Insighting the inhibitory potential of novel modafinil drug derivatives against estrogen alpha (ER\u03b1) of breast cancer through a triple hybrid computational methodology","volume":"366","author":"Saba","year":"2022","journal-title":"J. Mol. Liq."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2\u2212 metastatic breast cancer with an ESR1 mutation: Results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13058-024-01843-4","article-title":"Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer","volume":"26","author":"Greene","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.annonc.2023.09.3103","article-title":"Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2","volume":"34","author":"Damodaran","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"ref_63","first-page":"e37161","article-title":"The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells","volume":"7","author":"Fanning","year":"2018","journal-title":"Life"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1078-0432.CCR-12-3771","article-title":"Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: Implications for treatment of advanced disease","volume":"19","author":"Wardell","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1200\/JCO.2007.11.3886","article-title":"Selective estrogen-receptor modulators and antihormonal resistance in breast cancer","volume":"25","author":"Jordan","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bcp.12229","article-title":"Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer","volume":"77","author":"Brauch","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187221512799303118","article-title":"Pharmacogenomics of breast cancer targeted therapy: Focus on recent patents","volume":"6","author":"Yiannakopoulou","year":"2012","journal-title":"Recent Pat. DNA Gene Seq."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1535-7163.MCT-08-0447","article-title":"A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance","volume":"7","author":"Samaddar","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1080\/15548627.2017.1388476","article-title":"MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells","volume":"14","author":"Lee","year":"2018","journal-title":"Autophagy"},{"key":"ref_72","first-page":"349","article-title":"Estrogen receptor mutations in tamoxifen-resistant breast cancer","volume":"54","author":"Karnik","year":"1994","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ctrv.2011.08.003","article-title":"Pharmacogenetics of anti-estrogen treatment of breast cancer","volume":"38","author":"Michelucci","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/me.2016-1072","article-title":"Minireview: The Link Between ER\u03b1 Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer","volume":"30","author":"Basik","year":"2016","journal-title":"Mol. Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1677\/erc.1.01005","article-title":"Epidermal growth factor receptor\/HER2\/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer","volume":"12","author":"Gee","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.11-1-1","article-title":"Epigenetic information and estrogen receptor alpha expression in breast cancer","volume":"11","author":"Giacinti","year":"2006","journal-title":"Oncologist"},{"key":"ref_77","first-page":"1","article-title":"Tamoxifen in early-stage estrogen receptor-positive breast cancer: Overview of clinical use and molecular biomarkers for patient selection","volume":"4","author":"Criscitiello","year":"2010","journal-title":"Onco. Targets Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jnci\/djn177","article-title":"The rise of raloxifene and the fall of invasive breast cancer","volume":"100","author":"Jordan","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"68730","DOI":"10.18632\/oncotarget.19612","article-title":"Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics","volume":"8","author":"Sotgia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.3892\/or.2016.4675","article-title":"Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines","volume":"35","author":"Kim","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4161\/cbt.12.10.17780","article-title":"Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells","volume":"12","author":"Goldberg","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.4161\/cc.10.15.16584","article-title":"Understanding the metabolic basis of drug resistance: Therapeutic induction of the Warburg effect kills cancer cells","volume":"10","author":"Lin","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2014.05.006","article-title":"The impact of tumor stroma on drug response in breast cancer","volume":"31","author":"Dittmer","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): A multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1535-7163.MCT-20-0390","article-title":"SAR439859, a novel selective estrogen receptor degrader (SERD), demonstrates effective and broad antitumor activity in wild-type and mutant ER-positive breast cancer models","volume":"20","author":"Shomali","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10549-020-05575-9","article-title":"G1T48, an oral selective estrogen receptor degrader, and the CDK4\/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer","volume":"180","author":"Andreano","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: Recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/CAD.0000000000000271","article-title":"RAD1901: A novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models","volume":"26","author":"Garner","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/ERC-15-0287","article-title":"Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader","volume":"22","author":"Wardell","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-16-2561","article-title":"Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER+ breast cancer patient-derived xenograft models","volume":"23","author":"Bihani","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_97","unstructured":"Patel, H., Tao, J., Heike, A., and Bihani, T. (2018). Anti-Tumor Activity of Elacestrant (RAD1901) in Models Harboring ESR1 Mutations Resistant to Standard of Care Therapies, San Antonio Breast Cancer Symposium."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13058-019-1230-0","article-title":"Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4\/6 inhibitors","volume":"21","author":"Patel","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jcc.26076","article-title":"Investigation of binding mechanism and downregulation of elacestrant for wild and L536S mutant estrogen receptor-\u03b1 through molecular dynamics simulation and binding free energy analysis","volume":"41","author":"Chinnasamy","year":"2020","journal-title":"J. Comput. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/JCO.20.02272","article-title":"Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer","volume":"39","author":"Bardia","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41467-022-31668-8","article-title":"AMEERA-1 phase 1\/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive\/HER2-negative advanced breast cancer","volume":"13","author":"Bardia","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","article-title":"Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer","volume":"31","author":"Chen","year":"2022","journal-title":"Expert Opin. Investig. Drugs."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12282-023-01443-8","article-title":"Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)","volume":"30","author":"Tamura","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in E strogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","article-title":"Discovery of 6-(2,4-Dichlorophenyl)\u22125-[4-[(3S)\u22121-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]\u22128, 9-dihydro-7H-benzo [7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer","volume":"63","author":"Tabart","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2147\/DDDT.S380925","article-title":"Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status","volume":"16","author":"Downton","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4\/6 Inhibitor Resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_112","first-page":"1538","article-title":"SERENA-4: APhase IIIcomparison of AZD9833 (camizestrant) plus palbociclib versus anastrozole plus palbociclib for patients with ER-positive\/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease","volume":"82","author":"Im","year":"2022","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"PS12-04","DOI":"10.1158\/1538-7445.SABCS20-PS12-04","article-title":"Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+\/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection","volume":"81","author":"Aftimos","year":"2021","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/0008-5472.CAN-24-2608","article-title":"Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer","volume":"85","author":"Bhagwat","year":"2025","journal-title":"Cancer. Res."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Neupane, N., Bawek, S., Gurusinghe, S., Ghaffary, E.M., Mirmosayyeb, O., Thapa, S., Falkson, C., O\u2019Regan, R., and Dhakal, A. (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16030619"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2021.39.15_suppl.1050","article-title":"A first-in-human phase 1a\/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ERplus advanced breast cancer (aBC), endometrial endometrioid cancer (EEC): Results from the EMBER study","volume":"39","author":"Jhaveri","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Jhaveri, K.L., Jeselson, R., Lim, E., Hamilton, E.P., Yonemori, K., and Thaddeus, J. (2022, January 2\u20136). A phase 1a\/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER +) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER. Proceedings of the American Society of Clinical Oncology Annual Meeting 2022, Chicago, IL, USA.","DOI":"10.1200\/JCO.2022.40.16_suppl.1021"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1200\/JCO.23.02733","article-title":"Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia\/Ib EMBER Study","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"OT2","DOI":"10.1158\/1538-7445.SABCS21-OT2-11-01","article-title":"EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator\u2019s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy","volume":"82","author":"Jhaveri","year":"2022","journal-title":"Cancer Res."},{"key":"ref_122","unstructured":"(2024, January 02). A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05514054."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): An open-label, randomised, controlled, phase 2 study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Hernando, C., Ortega-Morillo, B., Tapia, M., Morag\u00f3n, S., Mart\u00ednez, M.T., Eroles, P., Garrido-Cano, I., Adam-Artigues, A., Lluch, A., and Bermejo, B. (2021). Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: Present and future from a clinical perspective. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157812"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1016\/j.annonc.2022.07.250","article-title":"Giredestrant (GDC-9545) vs. physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2\u2212 locally advanced\/metastatic breast cancer (LA\/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study","volume":"33","author":"Jimenez","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/07391102.2019.1574605","article-title":"Evaluation of binding and antagonism\/downregulation of brilanestrant molecule in estrogen receptor-\u03b1 via quantum mechanics\/molecular mechanics, molecular dynamics and binding free energy calculations","volume":"38","author":"Chinnasamy","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e15828","DOI":"10.7554\/eLife.15828","article-title":"The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer","volume":"5","author":"Joseph","year":"2016","journal-title":"Elife"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-022-06797-9","article-title":"The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + \/HER2 -) advanced\/metastatic breast cancer","volume":"197","author":"Bardia","year":"2023","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/715\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:18:33Z","timestamp":1783999113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":128,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cimb48070715"],"URL":"https:\/\/doi.org\/10.3390\/cimb48070715","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}